OCULAR THERAPEUTIX, INC Deferred Tax Assets, Capital Loss Carryforwards
OCULAR THERAPEUTIX, INC (OCUL) had Deferred Tax Assets, Capital Loss Carryforwards of $121.00 thousand as of 2023-12-31, per its 10-K filed 2025-03-03.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsCapitalLossCarryforwards · last filed 2025-03-03
- 2023-12-31: Deferred Tax Assets, Capital Loss Carryforwards $121.00K.
- 2022-12-31: Deferred Tax Assets, Capital Loss Carryforwards $255.00K.
- 2021-12-31: Deferred Tax Assets, Capital Loss Carryforwards $373.00K.
- 2020-12-31: Deferred Tax Assets, Capital Loss Carryforwards $514.00K.
| Period end | Deferred Tax Assets, Capital Loss Carryforwards |
|---|---|
| 2023-12-31 | $121.00K 10-K · filed 2025-03-03 |
| 2022-12-31 | $255.00K 10-K · filed 2024-03-11 |
| 2021-12-31 | $373.00K 10-K · filed 2023-03-06 |
| 2020-12-31 | $514.00K 10-K · filed 2022-02-28 |
| 2019-12-31 | $695.00K 10-K · filed 2021-03-11 |
| 2018-12-31 | $870.00K 10-K · filed 2020-03-12 |
| 2017-12-31 | $1.02M 10-K · filed 2019-03-07 |
| 2016-12-31 | $1.72M 10-K · filed 2018-03-08 |
| 2015-12-31 | $1.92M 10-K · filed 2017-03-10 |
| 2014-12-31 | $2.20M 10-K · filed 2016-03-10 |
| 2013-12-31 | $2.43M 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |